NCT04541082 2025-12-18Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System NeoplasmsJazz PharmaceuticalsPhase 1 Recruiting102 enrolled
NCT02549937 2024-07-10A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid TumorsHutchmedPhase 1/2 Completed130 enrolled 30 charts
NCT02736565 2023-11-13Pbi-shRNAâ„¢ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's SarcomaGradalis, Inc.Phase 1 Completed7 enrolled
NCT01222767 2021-10-29Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of ChemotherapyPharmaMarPhase 2 Completed17 enrolled 20 charts
NCT00668148 2018-07-17A Five-Tier, Open-Label Study of IMC-A12 in Advanced SarcomaEli Lilly and CompanyPhase 2 Completed113 enrolled 13 charts
NCT00563680 2016-10-27QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell TumorsNantCell, Inc.Phase 2 Completed38 enrolled
NCT00538850 2014-03-05Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainINSYS Therapeutics IncPhase 3 Completed130 enrolled 9 charts
NCT00006368 2013-05-01Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerNovartisPhase 1 Completed60 enrolled